Overview
Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Completed
Trial end date:
2010-05-01
2010-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the effects of AZD1656 on Sitagliptin pharmacokinetics and vice versa in patients with Type 2 Diabetes Mellitus.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AstraZenecaTreatments:
Sitagliptin Phosphate
Criteria
Inclusion Criteria:- Patients with confirmed type 2 diabetes mellitus for at least 2 months and treated
with metformin.
- Body mass index between ≥19 and ≤42 kg/m2.
Exclusion Criteria:
- Intake of another investigational drug within the last 30 days prior to enrolment.
- Clinically significant illness or clinically relevant trauma.